| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $178K-67.6% | $549K-67.9% | $1.7M |
| Total revenue | $425K+21.1% | $351K-49.8% | $699K+331.5% | $162K-98.4% | $10.2M+156.9% | $4.0M+70.8% | $2.3M |
| Cost of revenue | $71.0M+56.8% | $45.2M+6.2% | $42.6M-11.8% | $48.3M | $0 | $0 | — |
| Research and development | $475.3M+51.2% | $314.4M+30.3% | $241.2M+54.9% | $155.7M+15.1% | $135.3M+113.6% | $63.3M+38.2% | $45.8M |
| General and administrative | $176.6M-0.9% | $178.2M+60.8% | $110.8M+35.8% | $81.6M+41.5% | $57.7M+128.4% | $25.3M+33.3% | $19.0M |
| Total operating costs and expenses | $722.8M+34.4% | $537.8M+36.3% | $394.6M+38.2% | $285.6M+48.0% | $193.0M+117.8% | $88.6M | — |
| Loss from operations | -$648.1M-35.3% | -$479.0M-36.8% | -$350.1M-42.5% | -$245.7M-34.4% | -$182.8M-116.0% | -$84.6M-35.5% | -$62.4M |
| Other income, net | $3.2M-77.2% | $14.2M-20.7% | $17.9M+186.9% | $6.3M+268.8% | -$3.7M-54.9% | -$2.4M-525.4% | $562K |
| Loss before income tax benefit | -$644.9M-38.8% | -$464.8M-39.9% | -$332.1M-38.7% | -$239.5M-28.4% | -$186.5M | — | — |
| Income tax benefit | $136K-87.9% | $1.1M-72.3% | $4.1M | $0 | $0 | — | — |
| Net loss | -$644.8M-39.1% | -$463.7M-41.3% | -$328.1M-37.0% | -$239.5M-28.4% | -$186.5M-114.3% | -$87.0M-40.6% | -$61.9M |
| Net loss per share of class A, B and exchangeable common stock, basic (in dollars per share) | -$1440.00+14.8% | -$1690.00-7.0% | -$1580.00-16.2% | -$1360.00+8.7% | -$1490.00+62.7% | -$3990.00-138924.4% | -$2.87 |
| Net loss per share of class A, B and exchangeable common stock, diluted (in dollars per share) | -$1440.00+14.8% | -$1690.00-7.0% | -$1580.00-16.2% | -$1360.00+8.7% | -$1490.00+62.7% | -$3990.00-138924.4% | -$2.87 |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares) | 447.45B+63.2% | 274.21B+31.9% | 207.85B+18.4% | 175.54B+40.0% | 125.35B+475.5% | 21.78B+1.0% | 21.57B |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares) | 447.45B+63.2% | 274.21B+31.9% | 207.85B+18.4% | 175.54B+40.0% | 125.35B+475.5% | 21.78B+1.0% | 21.57B |
| Operating revenue | |||||||
| Grant revenue | |||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.